RENFLEXIS®


 
 
 
 
 
 
 
 
 


 

RENFLEXIS® (Infliximab-abda) a biosimilar to Remicade, is a drug used in the treatment of Inflammatory Bowel Disease, as well as other autoimmune diseases.

RENFLEXIS® is manufactured by Organon.

Administration and Dosage:

It is a weight-based medication following a recommended induction dose of 5mg/kg and maintenance dose of 10mg/kg (per Prescribing Doctor’s recommendation). The medication is infused intravenously in intervals at week 0, 2, 6 and then every 8 weeks for maintenance.

Common Side Effects:

The more common side effects of RENFLEXIS® include risk of infection.

More Information:

Please read the full Prescribing Information and Medication Guide for RENFLEXIS® and discuss any questions you have with your doctor.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

RENFLEXIS® is indicated to treat:

  • Crohn’s Disease
  • Ulcerative Colitis
  • Pediatric Ulcerative Colitis
  • Pediatric Crohn’s Disease
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Plaque Psoriasis